EC Number |
Application |
Reference |
---|
1.14.14.32 | drug development |
regioisomeric 17beta-N-phenylpyrazolyl steroid derivatives have weak inhibitory effect on 17alpha-hydroxylase/C17,20-lyase |
706778 |
1.14.14.32 | drug development |
silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases |
706689 |
1.14.14.32 | medicine |
combined 17alpha-hydroxyprogesterone aldolase/17,20-lyase deficiency is a rare, autosomal recessive form of congenital adrenal hyperplasia |
690654 |
1.14.14.32 | medicine |
homology modelling of the enzyme cytochrome P450 17alpha-hydroxylase/17,20-lyase (P450c17)-a target for prostate cancer chemotherapy-from the crystal structure of P450BM-3 |
5131 |
1.14.14.32 | medicine |
inhibition of 17alpha-hydroxylase-C(17,20)-lyase can block androgen synthesis at an early stage, and may therefore be useful in the treatment of prostatic carcinoma |
695147 |
1.14.14.32 | medicine |
inhibition of EC 4.1.2.30 is a potential therapeutic approach for the treatment of both breast and prostrate cancers |
5130 |
1.14.14.32 | medicine |
inhibitor VT-464 displays selective suppression of androgen synthesis through CYP17 lyase inhibition. VT-464 shows a greater decrease in androgen receptor transactivation than inhibitor abiraterone |
745754 |
1.14.14.32 | medicine |
inhibitors of 17alpha-hydroxylase/17,20 lyase are a class of anti-prostate cancer agents |
694115 |
1.14.14.32 | medicine |
inhibitors of 17alpha-hydroxylase/17,20 lyase are a new class of anti-prostate cancer agents |
694117 |
1.14.14.32 | medicine |
partial 17alpha-hydroxylase/17,20-lyase deficiency is a very rare form of congenital adrenal hyperplasia |
693809 |